TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence rate of calcium-phosphorus product levels greater than 65
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fever Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in anterior chamber inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exit site bacterial colonization status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complete response with negative minimal residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: The anti-MAGE-A3 seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The anti-protein D seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The anti-CpG seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The MAGE-A3 cellular (T cell) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of adverse events, including abnormal hematological and biochemical laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Plaque PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: changes in Hamilton Depression Rating Scale (HDRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cecal Intubation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Without Re-looping Among Those With Looping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor control (time up to progression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Coefficient of fat absorption (CFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attentional bias scores for positive social cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Effects of Alcohol Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Alcohol Urge Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Alcohol Sensitivity Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reactivity to alcohol cues: motivational approach bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of platelet-leukocyte aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum HR changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SPADI test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy and readiness scale Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients starting dialysis with an eGFR > 10.5 ml/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients starting dialysis as inpatients or in an emergency room
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of ductal lavage in detecting atypical cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Flow Measurements from the Lower Limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Percent Change From Baseline for Total PCB Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Change of Lipid Adjusted PCB Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: (re-)occlusion of the endarterectomized superficial femoral artery or suprageniculate femoropopliteal bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Emergency revisit rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percentage of OHCA patients with deranged physiology or complications upon hospital arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visceral and Subcutaneous Abdominal Adipose Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Lipid Panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in High-sensitivity C-reactive Protein (Hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Soluble Intercellular Adhesion Molecule-1 (sICAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients with Grade II-III Dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: survival without BPD at 36 weeks PMA
Endpoint domain: Mortality/survival
Primary endpoint: Change C-Telopeptide (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Serum Ionized Calcium (iCa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Total Ca
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Infusion Rate (GIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive culture for non-tuberculous mycobacteria (NTM)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of EVD Survivors With Evidence of Persistence of Ebola Viral RNA in Ocular Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of Intraocular Inflammation Between EVD Survivors and Controls at 1 Month Following Cataract Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Intraocular Inflammation Between EVD Survivors and Controls at 3 Months Following Cataract Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful initial hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gut microbiome species richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of sex hormone metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in total score of the Hamilton Anxiety Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3-Year Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Left ventricle systolic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricle systolic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Retention of study participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to consuming walnuts and EVOO
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunohistochemical staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Weekly Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: break-up time (BUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant's survival without CLD
Endpoint domain: Mortality/survival
Primary endpoint: shear wave elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surface electromyography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in end-diastolic dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in N-terminal pro-brain natriuretic peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Asthma symptom free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health care utilization for asthma
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in EQ ED
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in the Symptom Burden of Disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Quality of Life (Mood)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Quality of Life (Anxiety)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number and Severity of Infusion Site Reactions (ISRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in FIX Activity at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood thiamine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pulmonary complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Feasibility of Meaning-Centered Psychotherapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptability of Meaning-Centered Psychotherapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Insulin-stimulated whole body and organ-specific glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Epigenetic characterization of DNA samples (Telomere length, H2A.X phosphorilation, mtDNA deletion, p66)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with graft rupture
Endpoint domain: Adverse events/effects
Primary endpoint: acute pain model differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ T lymphopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 5R-STS performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: worsening of cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diabetes insipidus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroid hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Durable Fistula Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Malondialdehyde (MDA) levels in muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to Cardiac Rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Severity of COVID-19 Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily average pain rating with active range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum NTM Culture Conversion to Negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dystonia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Survival rate of the prosthesis at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Bayley Scales of Infant Development Version 3
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neutralising antibody to influenza subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of recatheterization
Endpoint domain: Adverse events/effects
Primary endpoint: Surface of the avascular zone in the central retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Amount of time spent in moderate to vigorous physical activity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Asthma Control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in parenting strengths and needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in parent/caregiver depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total energy expenditure during OGTT test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pharmacokinetics of norelgestromin, norgestrel, and ethinyl estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to the last measurable plasma concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent elimination half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological measures of HIV-related health status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to HIV/AIDS medical care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ST resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ab titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With First Cycle Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of SPI-1005
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Dizziness Handicap Inventory (DHI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relapse Free Survival at Month 12
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Grade 3 or Higher AEs, SAEs and Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Confirmed response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Alectinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-last]) of Alectinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Alectinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free fatty acid quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimum Plasma concentration (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of laparoscopic biopsy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of significant adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Neurodevelopmental outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Inflammation data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptoms data (BCSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HCV RNA concentrations in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in CD4+ T-cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood concentration of Nalbuphine HCl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic Stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Procedural Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with fully suppressed HIV RNA < 50 cps/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Metabolomics Biomarker Fingerprint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minnesota Handwriting Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum inhibin-B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: follicle number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: follicle size distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of successful blood withdrawals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adequate bowel preparation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of subjects with positive SN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolving of Headache at 60 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in net protein synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complete or Partial Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Dyspnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: independent living skills
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: social behavior skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: health behavior skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: preventive health care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Intensity for Overall Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With at Least 50% Pain Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of rescue opioid
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prognostic relevance of advanced imaging variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric quality of life (PedsQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HF Hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: CV Death
Endpoint domain: Mortality/survival
Primary endpoint: Change in health status of the intestinal tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: antepartum computerized cardiotocography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time that BIS range remains within 45 and 65
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of natalizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum observed concentration (Tmax) of natalizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve to the last measurable concentration (AUC0-last) of natalizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Unanticipated Adverse Device Effects (UADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bacteremia episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Normal Serum Conjugated Bilirubin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adherence to Truvada PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-related Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Highest VAS Pain Score at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated Change in Child Fruit & Vegetable Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Estimated Change in AHEI Healthy Foods Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes